Pharmaceutical

Alumis secures $259m to develop therapies for immune dysfunction

Alumis secured $259m in a Series C funding round to develop its clinical-stage pipeline of therapies designed to address immune dysfunction.

Mar 7, 2024 - 18:00
Alumis secures $259m to develop therapies for immune dysfunction
Alumis secured $259m in a Series C funding round to develop its clinical-stage pipeline of therapies designed to address immune dysfunction.
Read the original article

Tags:

Previous Article

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

Next Article

J&J seeks EU approval for new Darzalex multiple myeloma indication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Merck sues U.S. to halt Medicare drug-price negotiation; FDA oncology head wants advisory panels to keep voting on new drugs

STAT+: Pharmalittle: Merck sues U.S. to halt Medicare d...

Jun 6, 2023

STAT+: Former medical device CEO who sold dummy, plastic parts convicted of fraud

STAT+: Former medical device CEO who sold dummy, plasti...

Mar 8, 2024

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Associat...

Jun 14, 2023